Clinical Trials Logo

Memory clinical trials

View clinical trials related to Memory.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04392908 Active, not recruiting - Memory Clinical Trials

Communication Memory of Cancer Diagnosis Within the Pediatric Triangle

Start date: September 1, 2019
Phase:
Study type: Observational

Present project aims to investigate memories related to a cancer communication diagnosis in pediatric oncology. It evaluates possible common elements and specificity between family and healthcare staff.

NCT ID: NCT00972972 Active, not recruiting - Memory Clinical Trials

Effect of Bilberry (European Blueberries) and Grape Polyphenols on Cognition and Blood Parameters

BLUEBERRY
Start date: December 2006
Phase: Phase 0
Study type: Interventional

The purpose of this study is to determine whether dietary intervention with blueberry and grape juice extracts in elderly men with subjective memory problems would raise performance on neuropsychological memory tests and change biomarker of muscle damage and whole blood gene expression profiles.

NCT ID: NCT00893815 Active, not recruiting - HIV Infections Clinical Trials

Prevalence and Predictors of Neurocognitive Impairment Among HIV-infected Patients

Start date: April 2009
Phase:
Study type: Observational

Despite the advent of highly active antiretroviral therapy (HAART), the prevalence of neurocognitive impairment among HIV-infected patients continues to be an important issue. Although severe forms of AIDS-related dementia have diminished, milder forms of cognitive impairment have been noted among approximately 30% of asymptomatic HIV patients. Studies among HIV-infected U.S. military personnel regarding neurocognitive function have largely been limited to the early 1990s, before the advent of HAART. In these studies subtle neurobehavioral changes were noted among asymptomatic HIV-positive military personnel. This study proposes to determine the prevalence of neurocognitive deficits among HIV-positive military beneficiaries during the era of HAART who are participants of the U.S. Military HIV Natural History Study. The prevalence ascertained in this study will be compared to HIV-negative military beneficiaries who are demographically similar to the HIV positive group. The sample size of the study is to have complete testing on 200 HIV positive and 50 HIV-negative participants; due to the possibility of attrition before study completion, the investigators will enroll up to 300 participants (240 HIV-positive and 60 HIV-negative) to achieve this sample size. The investigators' rates among HIV-positive patients found in this study will also be contextualized in the setting of the prevalence of prior neurocognitive deficits seen in a HIV positive U.S. military population studied in the 1990s, contemporary rates among civilian HIV-infected persons, and normative values in the general HIV-negative population. Compared to other data in the field of neuropsychology, this study is novel in that the HIV population studied is composed largely of HIV patients who have been diagnosed early in their HIV infection; have open, free access to antiretrovirals to begin therapy earlier than most other cohorts; and consists of highly-functioning, educated individuals.